<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    10809994
   </pmid>
   <datecreated>
    <year>
     2000
    </year>
    <month>
     06
    </month>
    <day>
     19
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2000
    </year>
    <month>
     06
    </month>
    <day>
     19
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2007
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0954-6820
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       247
      </volume>
      <issue>
       5
      </issue>
      <pubdate>
       <year>
        2000
       </year>
       <month>
        May
       </month>
      </pubdate>
     </journalissue>
     <title>
      Journal of internal medicine
     </title>
     <isoabbreviation>
      J. Intern. Med.
     </isoabbreviation>
    </journal>
    <articletitle>
     Comparison of long versus short duration of anticoagulant therapy after a first episode of venous thromboembolism: a meta-analysis of randomized, controlled trials.
    </articletitle>
    <pagination>
     <medlinepgn>
      553-62
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To assess the length of oral anticoagulant therapy (short versus long duration) after a first episode of venous thromboembolism (VTE).
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      Meta-analysis of randomized controlled trials, comparing two durations of anticoagulation, identified in 1999 by a computerized search of the Cochrane Controlled Trial Register, Medline and Embase, completed by an extensive review of the references of pertinent articles.
     </abstracttext>
     <abstracttext label="SETTING AND SUBJECTS" nlmcategory="METHODS">
      The meta-analysis was performed on literature data. Seven published controlled trials were included. Relative risks with 95% confidence intervals were computed using the relative risk logarithm method. Statistical significance was set up at 0.01 for the test of association.
     </abstracttext>
     <abstracttext label="MAIN OUTCOME MEASURES" nlmcategory="METHODS">
      Outcomes are major haemorrhage and recurrence after a 12-month follow-up.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      For the recurrence end-point (sample size of 2304 patients), a duration treatment of 12-24 weeks seems preferable to a 3-6 week regimen, with a relative risk (RR) of 0.60 (95% CI: 0.45-0.79, P &lt; 0.001). For the major haemorrhage end-point (1823 patients), the RR is not significantly different from 1 (RR = 1.43, 95% CI: 0.51-4.01, P = 0. 5). The results were similar for the subgroup 'permanent risk factors' or 'idiopathic VTE' (RR for recurrence = 0.48, 95% CI: 0. 34-0.68, P &lt; 0.001). The tendency was similar, although not reaching statistical significance, for the 'temporary risk factors' subgroup (RR for recurrence = 0.34, 95% CI: 0.13-0.93, P = 0.035).
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      After a first episode of VTE, a long-term treatment regimen allows a significant reduction in the incidence of recurrences without increasing the incidence of bleeding events.
     </abstracttext>
    </abstract>
    <affiliation>
     Service de Médecine Interne, Hôpital Edouard Herriot, and Centre Cochrane Français, Unité de Pharmacologie Clinique, Lyon, France.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Pinede
      </lastname>
      <forename>
       L
      </forename>
      <initials>
       L
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Duhaut
      </lastname>
      <forename>
       P
      </forename>
      <initials>
       P
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Cucherat
      </lastname>
      <forename>
       M
      </forename>
      <initials>
       M
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Ninet
      </lastname>
      <forename>
       J
      </forename>
      <initials>
       J
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Pasquier
      </lastname>
      <forename>
       J
      </forename>
      <initials>
       J
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Boissel
      </lastname>
      <forename>
       J P
      </forename>
      <initials>
       JP
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Meta-Analysis
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     ENGLAND
    </country>
    <medlineta>
     J Intern Med
    </medlineta>
    <nlmuniqueid>
     8904841
    </nlmuniqueid>
    <issnlinking>
     0954-6820
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Anticoagulants
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      9005-49-6
     </registrynumber>
     <nameofsubstance>
      Heparin
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      J Intern Med. 2001 Sep;250(3):258-61
     </refsource>
     <pmid version="1">
      11555132
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      J Intern Med. 2000 Dec;248(6):531-3
     </refsource>
     <pmid version="1">
      11221728
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Acute Disease
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Administration, Oral
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Anticoagulants
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Heparin
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pulmonary Embolism
     </descriptorname>
     <qualifiername majortopicyn="N">
      etiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Randomized Controlled Trials as Topic
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Recurrence
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Risk Factors
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Survival Analysis
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Thromboembolism
     </descriptorname>
     <qualifiername majortopicyn="N">
      complications
     </qualifiername>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Time Factors
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2000
     </year>
     <month>
      5
     </month>
     <day>
      16
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2000
     </year>
     <month>
      6
     </month>
     <day>
      24
     </day>
     <hour>
      11
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2000
     </year>
     <month>
      5
     </month>
     <day>
      16
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     10809994
    </articleid>
    <articleid idtype="pii">
     jim631
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

